**Elevated Treasury yields near 19-year highs, combined with selective investor demand and post-SpaceX digestion, have driven multiple high-profile postponements and compressed timelines for IPO completions by December 31, 2026.** Oura recently delayed its planned listing citing market uncertainty despite strong interest, while EG Group, SB Energy, and Holtec have shifted plans into 2027 amid valuation pushback and volatility. OpenAI has signaled a 2027 preference, though Anthropic retains a possible mid-November window. Year-to-date U.S. activity remains robust with over 100 deals priced and substantial proceeds, supported by ongoing smaller filings and pricings such as TRex Bio and Retension Pharmaceuticals in early October. Key near-term catalysts include inflation releases, any FOMC communications, and company-specific announcements that could either accelerate filings or reinforce caution in the final quarter.